Table 1 Demographic and treatment characteristics
Covariate | All patients | Patients without irAEs G ≥ 2 | Patients with irAES G ≥ 2 | Healthy Controls | p-value* |
|---|---|---|---|---|---|
Total | 114 | 77 | 37 | 14 | Â |
Median Age | 61 (21–81) | 59 (21–81) | 65 (24–81) | 31 (18–58) | 0.070 |
Sex | |||||
 Male | 58 (51) | 34 (44) | 24 (65) | 5 (36) | 0.017 |
 Female | 56 (49) | 43 (56) | 13 (35) | 9 (64) |  |
History of prior autoimmune disease | |||||
 Yes | 8 (7) | 5 (6) | 3 (8) | NA | 0.90 |
 No | 106 (93) | 72 (94) | 34 (92) | NA |  |
Type of immunotherapy | Â | ||||
 Anti-PD1 | 102 (89) | 74 (96) | 28 (76) | NA |  |
 Anti-PD1 +  Anti-CTLA4 | 12 (11) | 3 (4) | 9 (24) | NA |  |
Tumor type | 0.022 | ||||
 HNSCC | 33 (29) | 20 (26) | 13 (35) | NA |  |
 Melanoma | 25 (22) | 9 (12) | 16 (43) | NA |  |
 TNBC | 22 (19) | 21 (27) | 1 (3) | NA |  |
 Others | 34 (30) | 27 (35) | 7 (19) | NA |  |
N of prior lines | 0.012 | ||||
 0 | 33 (29) | 13 (17) | 19 (51) | NA |  |
 1 | 38 (33) | 26 (34) | 14 (38) | NA |  |
 2 | 25 (22) | 20 (26) | 4 (11) | NA |  |
 ≥ 3 | 18 (16) | 18 (24) | 0 (0) | NA |  |
Prior Immunotherapy | 0.42 | ||||
 No | 109 (96) | 74 (96) | 34 (92) | NA |  |
 Yes | 5 (4) | 3 (4) | 3 (8) | NA |  |
Study | 0.039 | ||||
 INSPIRE | 84 (74) | 65 (84) | 19 (51) | NA |  |
 MET4 | 30 (26) | 12 (16) | 18 (49) | NA |  |